Sangamo BioSciences | SGMO - Umsatzkosten





Umsatzkosten Veränderung Datum
Alaunos Therapeutics USD 0 18K 2024-09
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
Bayer EUR 4.54B 692M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Cipla INR 29.71B 3.4B 2026-06
Clal Biotechnology ILS 16.49M 2.64M 2022-06
Compugen USD 1.82M 1.71M 2026-03
CSL USD 3.87B 2.08B 2025-12
Gilead Sciences USD 1000M 445M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Grifols EUR 1.51B 184.45M 2025-12
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
J&J USD 8B 67M 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
Merck USD 3.14B 200M 2026-06
Novartis USD 3.71B 251M 2026-06
Omeros USD 33.16M 18.52M 2024-06
Pfizer USD 4.09B 498M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.02B 656M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06